Alpha Cognition Inc
ACOG
株式のランク
#20064
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
株価
$8.66
最終同期: 2026-10-20
時価総額
$134.50M
変化（1日）
1.88%
変化（1年）
72.17%
国
US
取引 Alpha Cognition Inc (ACOG)
カテゴリー
Healthcare
Alpha Cognition Inc（ACOG）の収益
Jun 2026 時点の収益 TTM: $6.09M
Alpha Cognition Inc の最新の財務報告によると、現在の収益 (TTM) は $6.09M です。2022 年には 0.00 の収益があり、これは 2021 年の 0.00 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Alpha Cognition Inc の収益履歴（2018 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $6.09M | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 207,094.38% |
US
|
|
| $2.23B | 36,466.71% |
US
|
|
| $15.74B | 258,301.35% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 98,723.45% |
NL
|
